Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Boehringer Ingelheim
Citi
Moodys
Merck
Chubb
AstraZeneca
Accenture
Deloitte
Baxter

Generated: February 18, 2018

DrugPatentWatch Database Preview

Cubist Company Profile

« Back to Dashboard

Summary for Cubist
International Patents:256
US Patents:21
Tradenames:6
Ingredients:5
NDAs:6

Drugs and US Patents for Cubist

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Cubist Pharms Llc DIFICID fidaxomicin TABLET;ORAL 201699-001 May 27, 2011 RX Yes Yes 7,906,489 ➤ Try a Free Trial ➤ Try a Free Trial
Cubist Pharms Llc ZERBAXA ceftolozane sulfate; tazobactam sodium POWDER;IV (INFUSION) 206829-001 Dec 19, 2014 RX Yes Yes 7,129,232 ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Cubist Pharms Llc ZERBAXA ceftolozane sulfate; tazobactam sodium POWDER;IV (INFUSION) 206829-001 Dec 19, 2014 RX Yes Yes 8,906,898 ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Cubist Pharms Llc ZERBAXA ceftolozane sulfate; tazobactam sodium POWDER;IV (INFUSION) 206829-001 Dec 19, 2014 RX Yes Yes 8,476,425 ➤ Try a Free Trial Y ➤ Try a Free Trial
Cubist Pharms Llc SIVEXTRO tedizolid phosphate TABLET;ORAL 205435-001 Jun 20, 2014 RX Yes Yes 8,420,676 ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Cubist Pharms ENTEREG alvimopan CAPSULE;ORAL 021775-001 May 20, 2008 RX Yes Yes 6,469,030 ➤ Try a Free Trial ➤ Try a Free Trial
Cubist Pharms Llc ZERBAXA ceftolozane sulfate; tazobactam sodium POWDER;IV (INFUSION) 206829-001 Dec 19, 2014 RX Yes Yes 9,320,740 ➤ Try a Free Trial Y ➤ Try a Free Trial
Cubist Pharms Llc CUBICIN RF daptomycin POWDER;INTRAVENOUS 021572-003 Jul 6, 2016 RX Yes Yes 9,138,456 ➤ Try a Free Trial Y ➤ Try a Free Trial
Cubist Pharms Llc ZERBAXA ceftolozane sulfate; tazobactam sodium POWDER;IV (INFUSION) 206829-001 Dec 19, 2014 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial
Cubist Pharms Llc SIVEXTRO tedizolid phosphate TABLET;ORAL 205435-001 Jun 20, 2014 RX Yes Yes 7,816,379 ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for Cubist

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Cubist Pharms Llc CUBICIN daptomycin POWDER;IV (INFUSION) 021572-001 Sep 12, 2003 RE39071 ➤ Try a Free Trial
Cubist Pharms Llc CUBICIN daptomycin POWDER;INTRAVENOUS 021572-002 Sep 12, 2003 RE39071 ➤ Try a Free Trial
Cubist Pharms ENTEREG alvimopan CAPSULE;ORAL 021775-001 May 20, 2008 5,250,542 ➤ Try a Free Trial
Cubist Pharms Llc CUBICIN daptomycin POWDER;INTRAVENOUS 021572-002 Sep 12, 2003 5,912,226 ➤ Try a Free Trial
Cubist Pharms ENTEREG alvimopan CAPSULE;ORAL 021775-001 May 20, 2008 5,434,171 ➤ Try a Free Trial
Cubist Pharms Llc CUBICIN daptomycin POWDER;IV (INFUSION) 021572-001 Sep 12, 2003 5,912,226 ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for CUBIST drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Capsules 12 mg ➤ Subscribe 6/16/2017
➤ Subscribe Tablets 200 mg ➤ Subscribe 5/27/2015
➤ Subscribe For Injection 500 mg/vial ➤ Subscribe 11/19/2008

Non-Orange Book US Patents for Cubist

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,728,796 Tiacumicin production ➤ Try a Free Trial
8,835,382 Lipopeptide compositions and related methods ➤ Try a Free Trial
9,624,250 Forms of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5- -hydroxymethyl oxazolidin-2-one dihydrogen phosphate ➤ Try a Free Trial
7,696,220 Methods for the treatment or inhibition of ileus ➤ Try a Free Trial
9,662,397 Lipopeptide compositions and related methods ➤ Try a Free Trial
9,044,485 Ceftolozane antibiotic compositions ➤ Try a Free Trial
9,163,043 Oxazolidinone derivatives ➤ Try a Free Trial
7,507,564 Tiacumicin production ➤ Try a Free Trial
8,518,899 Macrocyclic polymorphs, compositions comprising such polymorphs and methods of use and manufacture thereof ➤ Try a Free Trial
8,883,986 Macrolide polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for Cubist Drugs

Supplementary Protection Certificates for Cubist Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2015000113 Germany ➤ Try a Free Trial PRODUCT NAME: CEFTOLOZAN ODER EIN PHARMAZEUTISCH VERTRAEGLICHEN SALZ DAVON, INSBESONDERE EIN SCHWEFELSAEURESALZ; REGISTRATION NO/DATE: EU/1/15/1032/001 20150918
2015 00048 Denmark ➤ Try a Free Trial PRODUCT NAME: TEDIZOLID, OPTIONALLY IN THE FORM OF AN ESTER, IN PARTICULAR A PHOSPHATE, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, INCLUDING TEDIZOLID PHOSPHATE; REG. NO/DATE: EU/1/15/991 20150325
3 50021-2015 Slovakia ➤ Try a Free Trial PRODUCT NAME: TEDIZOLIDFOSFAT; REGISTRATION NO/DATE: EU/1/15/991/001 - EU/1/15/991/003 20150325
C0062 France ➤ Try a Free Trial PRODUCT NAME: TEDIZOLIDE,EVENTUELLEMENT SOUS LA FORME D'UN ESTER ,EN PARTICULIER UN PHOSPHATE,OU L'UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/15/991 20150325
1539977/01 Switzerland ➤ Try a Free Trial PRODUCT NAME: FIDAXOMICIN; REGISTRATION NO/DATE: SWISSMEDIC 62957 01.05.2014
00727 Netherlands ➤ Try a Free Trial PRODUCT NAME: FIDAXOMICINE OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/11/733/001-004 20111205
0793 Netherlands ➤ Try a Free Trial PRODUCT NAME: CEFTOLOZAAN OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN IN HET BIJZONDER EEN ZWAVELZUURZOUT; REGISTRATION NO/DATE: EU/1/15/1032 20150922
00759 Netherlands ➤ Try a Free Trial PRODUCT NAME: TEDIZOLID, DESGEWENST IN DE; REGISTRATION NO/DATE: EU/1/15/991 20150323
/2015 Austria ➤ Try a Free Trial PRODUCT NAME: FIDAXOMICIN ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/11/733/001 - 004 (MITTEILUNG) 20111207
2015032,C1699784 Lithuania ➤ Try a Free Trial PRODUCT NAME: TEDIZOLIDAS, PASIRINKTINAI ESTERIO PAVIDALU, YPAC FOSFATO ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA; REGISTRATION NO/DATE: EU/1/15/991 20150323
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Teva
Cipla
Federal Trade Commission
Boehringer Ingelheim
McKinsey
QuintilesIMS
Farmers Insurance
Merck
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot